A study published in The New England Journal of Medicine has reported that the oral peptide icotrokinra, a selective interleukin-23 (IL-23) receptor blocker, achieved significantly greater skin clearance at 16 weeks compared with placebo in adults and adolescents with moderate-to-severe plaque psoriasis. This advancement marks a key step toward developing an oral biologic alternative for psoriasis management, offering a more convenient treatment option than injectable therapies. The authors note that ongoing research will be important to determine the long-term safety and durability of treatment response. The trial evaluated the efficacy and safety of icotrokinra in a randomized, placebo-controlled setting, with participants receiving oral doses of the peptide over 16 weeks. The therapy

See Full Page